AFACT Trial design: Patients with long-standing atrial fibrillation were randomized to ganglion plexus ablation (n = 117) vs. control (n = 123) on top.

Slides:

Advertisements

Similar presentations

Widimsky P, Tousek P, Rokyta R, et al. Charles University Prague, CZ PRAGUE-7 Study (Hot Lines presenter)

Advertisements

Ablation for Paroxysmal Atrial Fibrillation (APAF) Trial Presented at The American College of Cardiology Scientific Session 2006 Presented by Dr. Carlo.

Substrate and Trigger Ablation for Reduction of Atrial Fibrillation (STAR AF): a randomized, multicentre, international trial by Atul Verma, Roberto Mantovan,

SWEDMAF Trial Presented at The Heart Rhythm Society Meeting May 2006 Presented by Dr. Carina Blomstrom-Lundqvist SWEDMAF Trial.

Hsia J et al. J Am Coll Cardiol 2011;57: Baseline Characteristics by Treatment Group and Attained LDL-C Hsia J et al. J Am Coll Cardiol 2011;57:

One year follow-up after cryoballoon isolation of the pulmonary veins in patients with paroxysmal atrial fibrillation by Yves Van Belle, Petter Janse,

Date of download: 5/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: New Magnetic Resonance Imaging-Based Method for.

Date of download: 6/23/2016 Copyright © The American College of Cardiology. All rights reserved. From: Impact of CARDIOrespiratory FITness on Arrhythmia.

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Pulmonary Vein Total Occlusion Following Catheter.

Date of download: 7/11/2016 Copyright © The American College of Cardiology. All rights reserved. From: Movement of the Esophagus During Left Atrial Catheter.

Catheter Ablation of Atrial Fibrillation by Roderick Tung, Eric Buch, and Kalyanam Shivkumar Circulation Volume 126(2): July 10, 2012 Copyright.

Imaging and atrial fibrillation: the role of multimodality imaging in patient evaluation and management of atrial fibrillation by Laurens F. Tops, Martin.

Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Comparison of Radiofrequency Catheter Ablation of.

Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Gastrointestinal Bleeding in Patients With Atrial.

Recurrence of pulmonary vein conduction and atrial fibrillation after pulmonary vein isolation for atrial fibrillation: A randomized trial of the ostial.

Surgical treatment of atrial fibrillation: State of the art, 2012

(CMR vs. guidelines, p < 0.001)

EARLY-BAMI Trial design: Patients presenting with STEMI with a plan for primary PCI, and without evidence of cardiogenic shock, were randomized to either.

Circ Arrhythm Electrophysiol

RE-CIRCUIT Trial design: Patients with atrial fibrillation undergoing catheter ablation were randomized to uninterrupted dabigatran 150 mg twice daily.

(p < for group 1 or 2 vs. group 3)

Where does atrial fibrillation surgery fail

BENEFIT Trial design: Patients with positive serologic tests for T. Cruzi and cardiomyopathy were randomized to benznidazole 300 mg daily for days.

AcoArt I Trial design: Patients with femoropopliteal artery disease were randomized to paclitaxel-coated balloon angioplasty (n = 100) vs. standard peripheral.

Epicardial and endocardial electrophysiological guided thoracoscopic surgery for atrial fibrillation: A multidisciplinary approach of atrial fibrillation.

EUCLID Trial design: Patients with peripheral arterial disease (PAD) were randomized to ticagrelor 90 mg twice daily (n = 6,930) vs. clopidogrel 75 mg.

GLAGOV Trial design: Patients with CAD and elevated LDL cholesterol on statin therapy were randomized to subcutaneous evolocumab (n = 484) vs. subcutaneous.

TECAM Trial design: STEMI patients who underwent successful reperfusion therapy were randomized on day 1 to intracoronary bone marrow autologous mononuclear.

Second Chance for a Totally Thoracoscopic Video-Assisted Pulmonary Vein Isolation for Atrial Fibrillation Antoine H.G. Driessen, MD, Sébastien P.J. Krul,

(p for noninferiority = )

EVITA Trial design: Smokers admitted with an acute coronary syndrome were randomized to varenicline 1 mg twice daily (n = 151) vs. placebo (n = 151). Study.

INOVATE-HF Trial design: Patients with heart failure (HF) were randomized to device implant for vagus nerve stimulation (n = 436) versus optimal medical.

MAGIC-AF Trial design: Patients with persistent atrial fibrillation (AF) and remaining in AF after pulmonary vein isolation alone were randomized to either.

Losartan vs. Atenolol in Marfan Syndrome

POSEIDON-DCM Trial design: Patients with nonischemic dilated cardiomyopathy were randomized to transendocardial injection of allogenic (n = 18) vs. autologous.

Median total new lesion volume

Compare-Acute Trial design: STEMI patients undergoing primary PCI were randomized to fractional flow reserve (FFR)-guided complete revascularization (n.

Catheter Ablation for the Cure of Atrial Fibrillation Study

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

EXCITE ISR Trial design: Participants with femoropopliteal in-stent restenosis were randomized to excimer laser atherectomy + adjunctive angioplasty (n.

SMILE Trial design: NSTEMI patients were randomized to complete revascularization during the index procedure (i.e., 1-stage revascularization; n = 264)

FAMOUS-NSTEMI Trial design: Participants with NSTEMI were randomized to an FFR-guided strategy (n = 176) vs. a coronary angiography-guided strategy (n.

EVERBIO II Trial design: Patients with CAD were randomized in a 1:1:1 fashion to either Absorb BVS, Biomatrix Flex stent [BES], or Promus Element EES.

Gaurav A. Upadhyay, MD, Jonathan S. Steinberg, MD Heart Rhythm

BAT for HFrEF Trial design: Patients with chronic systolic HF were randomized in a 1:1 fashion to either baroreceptor activation therapy (BAT) or control.

ZEUS Trial design: Patients who were deemed uncertain DES candidates due to bleeding, thrombotic, or restenosis risk were randomized to receive either.

Sébastien P.J. Krul et al. JACEP 2015;1:

TACTICS-HF Trial design: Patients with acute heart failure (reduced or preserved ejection fraction) were randomized to tolvaptan 30 mg at 0, 24, and 48.

Volume 12, Issue 9, Pages (September 2015)

AMACING Trial design: Patients with chronic kidney disease undergoing intravascular iodinated contrast administration were randomized to prophylactic hydration.

(p < for noninferiority)

BRAVO-3 Trial design: Patients undergoing transfemoral TAVR were randomized in a 1:1 fashion to bivalirudin or UFH. They were followed for 30 days. Results.

Catheter Ablation for Atrial Fibrillation

Amir Jadidi et al. JACEP 2018;4:

Stavros Stavrakis et al. JACEP 2015;1:1-13

(p = for noninferiority)

Epicardial and endocardial electrophysiological guided thoracoscopic surgery for atrial fibrillation: A multidisciplinary approach of atrial fibrillation.

Pouria Alipour et al. JACEP 2017;j.jacep

The procedural journey for our cohort of patients with persistent atrial fibrillation. The procedural journey for our cohort of patients with persistent.

K.R. Julian Chun et al. JACEP 2017;3:

CHAMPION Trial design: Patients with recent hospitalization for heart failure were implanted with a pulmonary artery pressure monitor and randomized so.

Moussa Mansour et al. JACEP 2016;j.jacep

SOLID-TIMI 52 Trial design: Participants within 30 days of an acute coronary syndrome (ACS) were randomized to darapladib 160 mg daily (n = 6,504) versus.

IVUS-XPL Trial design: Patients undergoing drug-eluting stent implantation for long coronary lesions were randomized to IVUS-guided PCI (n = 700) vs. angiography-guided.

IMPRESS Trial design: Patients undergoing primary PCI for STEMI and cardiogenic shock were randomized in a 1:1 to either Impella CP or IABP. They were.

(p for noninferiority = 0.01)

MATRIX: Radial vs. Femoral

Left Atrial Fibrosis Assessed with Cardiac MRI in Patients with Paroxysmal and Those with Persistent Atrial Fibrillation More than two left atrial segments.

Demographic Characteristics of Patients Treated With Statins Versus Those Not Treated With Statins Goldberger JJ, et al. J Am Coll Cardiol 2006;48:

Stavros Stavrakis et al. JACEP 2015;1:1-13

Presentation transcript:

AFACT Trial design: Patients with long-standing atrial fibrillation were randomized to ganglion plexus ablation (n = 117) vs. control (n = 123) on top of pulmonary vein isolation and additional left atrial lines via thoracoscopy. Results (p = 0.70) No atrial fibrillation recurrences: 70.9% of the ganglion plexus group vs. 68.4% of the control group (p = 0.70) Total procedure-related adverse events: 19% in the ganglion plexus group vs. 8% in the control group (p = 0.022) Bleeding: 8% in the ganglion plexus group vs. 0 in the control group (p = 0.001) 70.9 68.4 % Conclusions Among patients with long-standing atrial fibrillation, ganglion plexus block was unsuccessful at achieving a higher frequency of freedom from atrial fibrillation in addition to pulmonary vein isolation Ganglion plexus block Control Driessen AH, et al. J Am Coll Cardiol 2016;68:1155-65